CRSP – CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSP

$54.83

Name : CRISPR Therapeutics AG

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $5,262,874,624.00

EPSttm : -6.47

CRISPR Therapeutics AG

$54.83

7.05%

$3.61

CRSP — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

25.39

Margin Of Safety %

Put/Call OI Ratio

0.53

EPS Next Q Diff

0.13

EPS Last/This Y

1.53

EPS This/Next Y

0.75

Price

54.81

Target Price

79.83

Analyst Recom

1.9

Performance Q

1.84

Upside

-515.6%

Beta

1.8

Ticker: CRSP

17 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-17	CRSP	50.09	0.56	0.29	81529
2026-03-18	CRSP	47.67	0.56	0.48	82616
2026-03-19	CRSP	46.61	0.56	0.34	83192
2026-03-20	CRSP	46.26	0.55	1.25	83111
2026-03-23	CRSP	46.87	0.57	0.31	74043
2026-03-24	CRSP	46.39	0.56	0.35	75870
2026-03-25	CRSP	47.1	0.55	0.41	77020
2026-03-26	CRSP	47.57	0.55	0.37	77619
2026-03-27	CRSP	45.76	0.55	0.81	78493
2026-03-30	CRSP	44.33	0.55	0.63	75436
2026-03-31	CRSP	47.41	0.54	0.18	76220
2026-04-01	CRSP	48.8	0.53	0.24	77862
2026-04-02	CRSP	49.5	0.53	0.45	78637
2026-04-06	CRSP	49.14	0.52	0.77	76773
2026-04-08	CRSP	51.76	0.52	0.41	78846
2026-04-09	CRSP	51.75	0.52	1.60	79419
2026-04-13	CRSP	54.82	0.53	0.24	77787
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

17 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-17	CRSP	50.11	21.6	107.0	-4.94
2026-03-18	CRSP	47.67	21.6	177.2	-4.94
2026-03-19	CRSP	46.92	21.6	150.5	-4.94
2026-03-20	CRSP	46.24	21.4	149.8	-4.94
2026-03-23	CRSP	46.86	21.4	124.9	-4.94
2026-03-24	CRSP	46.35	21.4	146.6	-4.94
2026-03-25	CRSP	47.10	21.4	124.2	-4.94
2026-03-26	CRSP	47.56	21.4	128.1	-4.94
2026-03-27	CRSP	45.74	21.4	169.4	-4.94
2026-03-30	CRSP	44.32	21.4	164.3	-4.94
2026-03-31	CRSP	47.58	21.4	70.9	-4.94
2026-04-01	CRSP	48.81	21.4	114.2	-4.94
2026-04-02	CRSP	49.51	21.4	124.4	-4.94
2026-04-06	CRSP	49.13	21.4	143.1	-4.94
2026-04-07	CRSP	49.74	21.4	126.2	-4.94
2026-04-08	CRSP	51.76	21.4	101.9	-4.94
2026-04-09	CRSP	51.74	21.4	137.0	-4.94
2026-04-10	CRSP	51.24	21.4	144.3	-4.94
2026-04-13	CRSP	54.81	21.6	78.9	-4.94
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-17	CRSP	-3.73	4.62	24.21
2026-03-18	CRSP	-3.73	4.62	24.21
2026-03-19	CRSP	-3.73	4.62	24.21
2026-03-20	CRSP	-3.73	4.62	24.21
2026-03-23	CRSP	-3.73	4.59	24.21
2026-03-24	CRSP	-3.96	4.59	24.21
2026-03-25	CRSP	-3.96	4.59	24.35
2026-03-26	CRSP	-3.96	4.59	24.35
2026-03-27	CRSP	-3.96	4.59	24.35
2026-03-30	CRSP	-3.96	4.59	24.35
2026-03-31	CRSP	-3.96	4.59	24.35
2026-04-01	CRSP	-3.96	4.59	24.35
2026-04-02	CRSP	-3.96	4.59	24.35
2026-04-06	CRSP	-3.96	4.59	24.35
2026-04-07	CRSP	-3.96	4.59	24.35
2026-04-08	CRSP	-3.96	4.59	24.35
2026-04-09	CRSP	-3.96	4.59	24.35
2026-04-10	CRSP	-3.96	4.59	24.35
2026-04-13	CRSP	-3.96	4.47	25.39
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.37

Avg. EPS Est. Current Quarter

-1.24

Avg. EPS Est. Next Quarter

-1.24

Insider Transactions

-3.96

Institutional Transactions

4.47

Beta

1.8

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.7

Max Drawdown 5-Year %

-80.7

Target Price

79.83

P/E

Forward P/E

PEG

P/S

1499.4

P/B

2.74

P/Free Cash Flow

EPS

-6.51

Average EPS Est. Cur. Y

-4.94

EPS Next Y. (Est.)

-4.19

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-16569.77

Relative Volume

0.98

Return on Equity vs Sector %

-57.6

Return on Equity vs Industry %

-41.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

78.9

◆ CRSP Healthcare

$54.83

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

6/25

Volume

7/15

Valuation

12/20

TP/AR

1/10

Options

5/10

RSI

61.9

Range 1M

99%

Sup Dist

9.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

11/30

Estimates

0/20

Inst/Vol

7/15

Options

8/10

EPS Yr

24.9%

EPS NY

22.2%

52W%

48.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +45.6% upside

Quality

2/30

Valuation

12/30

Growth

11/25

Stability

8/10

LT Trend

1/5

Upside

+45.6%

Quality

CRISPR Therapeutics AG

Sector: Healthcare

Industry: Biotechnology

Employees:

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRSP

Latest News

—

Caricamento notizie per CRSP…

stock quote shares CRSP – CRISPR Therapeutics AG Stock Price stock today

news today CRSP – CRISPR Therapeutics AG stock forecast ,stock prediction 2023 2024 2025

marketwatch CRSP – CRISPR Therapeutics AG yahoo finance google finance

stock history CRSP – CRISPR Therapeutics AG invest stock market

stock prices CRSP premarket after hours

ticker CRSP fair value insiders trading

CRSP – CRISPR Therapeutics AG

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: CRSP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y